

## In the Claims

Please amend the claims as follows:

1. (CURRENTLY AMENDED) An isolated mammalian-nucleic acid molecule selected from the group consisting of:

(a) nucleic Nucleic-acid molecules encoding T128 polypeptide (SEQ ID NO: 1) as shown in Figure 1, a polypeptide at least 80% identical to SEQ ID NO: 1T128, or a fragment thereof, which is capable of cross-reacting with sera from patients with prostate cancer.

(b) nucleic Nucleic-acid molecules comprising the nucleotide sequence depicted between nucleic acid residues 642 and 1688 of SEQ ID NO: 2; the sequence shown in Figure 2.

(c) nucleic Nucleic-acid molecules, the complementary strand of which specifically hybridises to a nucleic acid molecule in (a) or (b); and

(d) nucleic Nucleic-acid molecules the sequence of which differs from the sequence of the nucleic acid molecule of (C) in (a), (b), or (c) due to the degeneracy of the genetic code.

2. (CURRENTLY AMENDED) An isolated nucleic acid molecule according to claim 2 or claim 1, encoding the polypeptide sequence shown in Figure 1 of SEQ ID NO: 1.

3. (CURRENTLY AMENDED) An isolated nucleic acid molecule which is at least 80% homologous to a nucleic acid sequence molecule according to as defined in claim 1 or claim 2 and which encodes a polypeptide which is expressed in higher concentrations in cancerous tissue compared to that tissue when in a normal state.

4. (CURRENTLY AMENDED) An isolated nucleic acid molecule comprising at least 15 nucleic acids capable of specifically hybridising to a sequence within a nucleic acid molecule according to claim 1 or any preceding claim.

5. (CURRENTLY AMENDED) A vector comprising a nucleic acid molecule according to claim 1 or any preceding claim.

6. (CURRENTLY AMENDED) A host cell comprising a vector according to claim 5.

7. (CURRENTLY AMENDED) An isolated protein comprising an amino acid sequence encoded by a nucleic acid molecule according to claim 1~~any preceding claim~~.

8. (CURRENTLY AMENDED) An isolated protein according to claim 7 which comprises the amino acid sequence of SEQ ID NO: 1~~shown in Figure 1~~.

9. (CURRENTLY AMENDED) A fragment or derivative of a polypeptide~~the protein~~ according to claim 7 or claim 8.

10. (CURRENTLY AMENDED) A monoclonal antibody capable of specifically binding to a-the protein of claim 7, polypeptide, or a fragment or derivative thereof~~according to any one of claims 7 to 9~~.

11. to 12. (CANCELED)

11. (ORIGINAL) ~~The use of an isolated nucleic acid molecule comprising a sequence according to any one of claims 1 to 4 to detect or monitor cancer.~~

12. (ORIGINAL) ~~The use of a nucleic acid probe which is capable of specifically hybridising an isolated nucleic acid molecule according to any of claims 1 to 4.~~

13. (CURRENTLY AMENDED) A method of detecting or monitoring cancer in a patient comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising a sequence~~the nucleic acid molecule~~ according to claims 1 to 4~~claim 1~~ in a sample from a-the patient.

14. (CURRENTLY AMENDED) A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 use of a nucleic acid molecule or probe according to claim 11 or claim 12 in combination with a reverse transcription polymerase chain reaction (RT PCR).

15. (CURRENTLY AMENDED) A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a polypeptide~~the protein~~ according to claim 7~~any of claims 7 to 9~~.

16. (CURRENTLY AMENDED) A The method according to claim 15 wherein the detecting or monitoring step includes a monoclonal comprising the use of an antibody selective for and capable of a protein or peptide as defined in any of claims 7 to 9 to detecting the protein or peptide.

17. (CURRENTLY AMENDED) A The method according to claim 16  
wherein the detecting or monitoring step includes an Enzyme-Linked ImmunoSorbant Assaycomprising the use of an Enzyme linked ImmunoSsorbant Assay (ELISA).

18. (CURRENTLY AMENDED) Use or The method according to claim 13  
any one of claims 11 to 17, wherein the cancer is a gastro-intestinal cancer, kidney cancer or a prostate cancer.

19. (CURRENTLY AMENDED) A kit comprising the nucleic acid molecule as defined in claim 1 for use with a method of detecting or monitoring canceraccording to any one of claims 13 to 18 comprising a nucleic acid, protein or peptide, or an antibody as defined in any one of claims 1 to 4 or 8 to 10.

20. (CURRENTLY AMENDED) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of a nucleic acid molecule comprising athe nucleic acid sequence molecule according to claim 1 any of claims 1 to 4 or a pharmaceutically effective fragment thereof.

21. (CURRENTLY AMENDED) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of a nucleic acid molecule hybridisable under high stringency conditions to a nucleic acid molecule comprising athe nucleic acid sequence molecule according to claim 1 any of claims 1 to 4 or a pharmaceutically effective fragment thereof.

22. (CURRENTLY AMENDED) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of a polypeptide the protein according to claim 7 as defined in any of claims 7 to 9 or a pharmaceutically effective fragment thereof.

23. (CURRENTLY AMENDED) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of anthe monoclonal antibody according to claim 10 claim 11.

24. (CURRENTLY AMENDED) AThe method according to claim 20 any one of claims 20 to 23, wherein the cancer is a gastro-intestinal cancer.

25. (CURRENTLY AMENDED) A vaccine comprising a nucleic acid molecule having acomprising the nucleic acid molecule according to claim 1 sequence as defined in any of claims 1 to 4 or a pharmaceutically effective fragment thereofthereof, and a pharmaceutically acceptable carrier.

26. (CURRENTLY AMENDED) A vaccine comprising a polypeptide ~~the protein~~ according to claim 7 ~~any of claims 7 to 9~~ or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.

27. (CURRENTLY AMENDED) A ~~The~~ polypeptide according to claim 7 ~~claims 7 to 9~~ or a pharmaceutically effective fragment thereof, attached to a carrier ~~protein~~ protein.

28. (NEW) A kit comprising the protein according to claim 7 for use with a method of detecting or monitoring cancer.

29. (NEW) A kit comprising the monoclonal antibody according to claim 10 for use with a method of detecting or monitoring cancer.

30. (NEW) An immunogenic composition comprising a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.

31. (NEW) An immunogenic composition comprising the protein according to claim 7 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.